Form 483

Central Admixture Pharmacy Services, Inc. Form 483, 2022-02-25

FDA issued a Form 483 to Central Admixture Pharmacy Services, Inc. on 2022-02-25 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

Central Admixture Pharmacy Services, Inc. · Phoenix, United States · Issued February 25, 2022

Overview

  • 6 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

25 Feb 2022
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Christopher M Jenner, Gunneet Kaur

25 Feb 2022
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Christopher M Jenner, Gunneet Kaur

25 Feb 2022
21 CFR 211.194(a)(5)

Calculations performed are in the records

Cited by Christopher M Jenner, Gunneet Kaur

25 Feb 2022
21 CFR 211.42(c)(10)(vi)

Equipment to control conditions

Cited by Christopher M Jenner, Gunneet Kaur

25 Feb 2022
21 CFR 211.67(a)

Cleaning / Sanitizing / Maintenance

Cited by Christopher M Jenner, Gunneet Kaur

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(5)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(vi)Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x
21 CFR 211.68(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere